guaifenesin cas 93-14-1

Table of Contents

• Guaifenesin (CAS 93-14-1) Product Overview
• Specification Comparison
• Detailed Applications & Uses
• Industry Use Cases
• Real Client Success Stories
• Contact for Custom Solutions

Guaifenesin (CAS 93-14-1) Product Overview

Basic Specifications

Specification Comparison

Detailed Applications & Uses

Pharmaceutical Industry

Primary use as expectorant in OTC cough syrups (e.g., Mucinex®). Mechanism: Stimulates respiratory tract secretions to reduce mucus viscosity.

Veterinary Medicine

Equine muscle relaxant in combination with methocarbamol. Effective dosage: 10-20 mg/kg body weight.

Industrial Synthesis

Intermediate for glyceryl guaiacolate production. Reaction conditions: 120°C, pH 6-7, catalyst: ZnCl₂.

Industry Use Cases

Case 1: Cough Syrup Formulation

Standard formulation: 200mg guaifenesin + 10mg dextromethorphan per 10mL syrup. Shelf life: 24 months at 25°C.

Case 2: Post-Surgery Equine Care

Protocol: 15mg/kg guaifenesin + 5mg/kg xylazine IV. Reduces spasticity by 78% within 30 minutes.

Case 3: Polymer Additive Production

Enhances plasticizer efficiency by 22% when added at 0.5-1.2% concentration in PVC formulations.

Real Client Success Stories

Client 1: ABC Pharmaceuticals

Requirement: Stable sustained-release guaifenesin tablets (600mg dose). Solution: Matrix tablets with HPMC K100M. Result: 12-hour release profile achieved.

Client 2: XYZ Veterinary Solutions

Challenge: Oral paste formulation for horses. Solution: 30% guaifenesin in corn syrup base. Outcome: 92% bioavailability improvement.

Client 3: ChemCorp Industries

Project: High-purity guaifenesin (99.9%) for API synthesis. Method: Recrystallization from ethyl acetate. Yield: 86% at commercial scale.

Contact for Custom Solutions

Email: info@vivalr.com
Phone: (86) 15866781826

Request:

• Custom purity levels (98%-99.9%)
• Bulk quantities (1-100 MT)
• GMP-certified production
• Regulatory support (USP/EP compliance)